![Patheon On Keeping Up With Biologics Demand Patheon On Keeping Up With Biologics Demand](https://eu-images.contentstack.com/v3/assets/blt0a48a1f3edca9eb0/blt4a62fd6fadf30f8c/658aeff9ab6e95040a409132/outsource.jpg?width=1280&auto=webp&quality=95&format=jpg&disable=upscale)
Patheon is doubling its biomanufacturing capacity through a $50 million investment in Missouri. We spoke with the CDMO about the continued demand for biologics services and its relationship with owner Thermo Fisher.
In April, contract development and manufacturing organization (CDMO) Patheon announced plans to add 16,000 L of single-use capacity at its St Louis, Missouri facility.
The US$50 million (€43 million) expansion effectively doubles the firm’s global biomanufacturing capacity. According to David Kenyon, senior director of Global Scientific and Technical Affairs at Patheon Biologics, this is the latest in a continued investment strategy aimed at keeping up with the demand for its services.
“We’re seeing throughout our network an increase in capacity needs for biologics, both in the US and across our network overseas,” he told BioProcess Insider at the BIO convention in Boston. “[The Missouri expansion] is about 65,000 square feet, which will help us supply the market and service our customers’ needs going forward.”
Interviewed as part of the Insider Daily series at the BPI Theater, Kenyon said the firm has also expanded its process development services several times over the past few years to keep up with the demand.
“Every time we say this will be enough space and enough needs, we find that customer needs grow.”
He added: “We’re going to keep pace with that, whether it’s in the development or clinical or commercial manufacturing space. We now have three manufacturing sites which we’ve expanded over recent years and going forward we will expand as the demand comes up.”